Yarrow Bioscience, Inc. (YARW)
NASDAQ: YARW · Real-Time Price · USD
30.91
+2.86 (10.18%)
Jul 29, 2026, 4:00 PM EDT - Market closed
Company Description
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
The company’s candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease and thyroid eye disease.
The company was incorporated in 2025 and is based in New York, New York.
Yarrow Bioscience, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Rebecca Velez Frey |
Contact Details
Address: 40 10 th Avenue, Floor 7 New York, New York 10014 United States | |
| Website | yarrowbioscience.com |
Stock Details
| Ticker Symbol | YARW |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Reporting Currency | USD |
| CIK Code | 1566044 |
| CUSIP Number | 92941V407 |
| ISIN Number | US92941V4077 |
Key Executives
| Name | Position |
|---|---|
| Rebecca Velez Frey | President and Chief Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 28, 2026 | 8-K | Current Report |
| Jul 21, 2026 | 8-K | Current Report |
| Jul 20, 2026 | 8-K | Current Report |
| Jul 17, 2026 | SCHEDULE 13G/A | Filing |
| Jul 14, 2026 | SCHEDULE 13G/A | Filing |
| Jul 14, 2026 | 425 | Filing |
| Jul 14, 2026 | 8-K | Current Report |
| Jul 10, 2026 | 425 | Filing |
| Jul 10, 2026 | 8-K | Current Report |
| Jun 16, 2026 | ARS | Filing |